Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF

Core Insights - Tenax Therapeutics is hosting a conference call on November 13, 2025, to discuss the treatment landscape for pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF) and the ongoing development of TNX-103 [1][2] Company Overview - Tenax Therapeutics is a Phase 3, development-stage pharmaceutical company focused on novel cardiopulmonary therapies, specifically targeting PH-HFpEF, which currently lacks approved treatments [5] - The company has global rights to develop and commercialize levosimendan, a first-in-class K-ATP channel activator/calcium sensitizer [4][5] Product Development - TNX-103 (oral levosimendan) is being advanced in two registrational Phase 3 studies, LEVEL and LEVEL-2, with enrollment ongoing in the North American LEVEL study and the global LEVEL-2 study set to initiate in 2025 [3] - Previous studies, including the Phase 2 HELP study, indicated that both intravenous (TNX-101) and oral (TNX-103) formulations of levosimendan could improve exercise capacity and quality of life in patients with PH-HFpEF [4]